Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01427244
Recruitment Status : Withdrawn
First Posted : September 1, 2011
Last Update Posted : June 16, 2014
Genentech, Inc.
Information provided by (Responsible Party):
Yale University

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : September 2014
  Estimated Study Completion Date : September 2015